Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

rVSV-ZEBOV vaccine first real-world data support prophylactic use for future Ebola outbreaks, says GlobalData

The rVSV-ZEBOV vaccine has demonstrated real-world effectiveness of approximately 84% against Ebola virus disease, revealed a recent study carried out by researchers in Europe and the Democratic Republic of the Congo (DRC). This retrospective, test-negative study, which analyzed 618 individuals during the 2018-2020 Ebola virus epidemic in the DRC, supports the prophylactic use of rVSV-ZEBOV […]
Read more

China pharma firms eye stronghold in therapeutic cancer vaccines market, says GlobalData

Cancer vaccines represent a burgeoning field in oncology, with the potential to revolutionize cancer treatment. Earlier, approved cancer vaccines were prophylactic against cancer-causing viruses. However, recent advancements have shifted towards developing therapeutic cancer vaccines, which focus on identifying tumor-specific antigens to create innovative cancer immunotherapies. In this context, Chinese companies are actively positioning themselves to […]
Read more

Gilead’s Livdelzi wins FDA approval, challenges Ocaliva dominance in primary biliary cholangitis market, says GlobalData

Gilead Sciences has recently announced the US FDA’s approval of seladelpar, its PPAR-δ agonist, under the brand name Livdelzi, for primary biliary cholangitis (PBC). This major turnaround for seladelpar, once a failed non-alcoholic steatohepatitis (NASH) asset, follows Gilead’s acquisition of the asset’s developer, Cymabay Therapeutics, earlier this year. The approval could present a major challenge […]
Read more

GLP-1R market: A two horse race, says GlobalData

The popularity of glucagon-like peptide-1 receptor (GLP-1R) drugs has exploded in recent years due to their abilities in effectively treating metabolic-related disorders such as obesity and type 2 diabetes. As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase fourfold to an estimated $142 billion […]
Read more

Pharma CMO M&A activity shifts focus to scaling in 2023, reveals GlobalData

Merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry declined in 2023 compared to 2021-22. High inflation and interest rates along with an uncertain business environment disincentivized investment. Despite fewer deals, the focus shifted towards scaling operations rather than acquiring specialized capabilities, according to GlobalData, a leading data and analytics company. Adam Bradbury, […]
Read more

Scholar Rock’s apitegromab holds potential to become first myostatin inhibitor for SMA patients, says GlobalData

As part of its Q2 2024 Financial Results and Business Progress reporting, Scholar Rock disclosed new positive data from its Phase II TOPAZ trial, with results showing continued and sustained motor function over four years in non-ambulatory patients with spinal muscular atrophy (SMA) treated with apitegromab and nusinersen. The positive data lays the foundation for […]
Read more

Atopic dermatitis treatment sees promising future with new drug approvals, says GlobalData

Atopic dermatitis (AD) is experiencing a transformative shift in treatment management with recent drug approvals that address critical unmet needs. The introduction of novel therapies, such as Dermavant’s VTAMA (tapinarof) (Japan) and Arcutis’s ZORYVE (roflumilast) (US), with innovative mechanisms of action, offers hope for improved patient outcomes. As these treatments enter the market, they underscore […]
Read more

Eli Lilly obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition, says GlobalData

Eli Lilly’s tirzepatide (Mounjaro) has recently been approved by the National Medical Products Administration (NMPA) for treating obesity. This approval, based on the positive results from the SURMOUNT-CN clinical trial, makes tirzepatide the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for obesity treatment in China, which is expected to […]
Read more

Viking Therapeutics’ obesity drug could become direct competitor to Eli Lilly’s tirzepatide, says GlobalData

The obesity market continues to expand, but therapeutic options remain limited and shortages in supply continue. This creates a significant opportunity for new entrants. Numerous companies are exploring potential breakthrough mechanisms of action beyond GLP-1R agonists, while others are focusing on the synergistic effects of targeting multiple receptors to enhance the benefits of GLP-1R agonists. […]
Read more

Zydus and Roche legal battle highlights need for affordable breast cancer treatments in India, says GlobalData

Zydus Life Sciences is engaged in a legal battle with Roche over its biosimilar, Sigrima, which is based on Roche’s Perjeta (Pertuzumab), targeting the human epidermal growth factor receptor 2-positive (HER2+) breast cancer market in India. As cases of HER2+ breast cancer rise in the country, the conflict underscores the critical need for cost-effective biosimilars […]
Read more

Sionna and AbbVie deal can redefine cystic fibrosis therapeutics, says GlobalData

Sionna Therapeutics, a US-based clinical-stage life sciences company specializing in cystic fibrosis (CF), has secured exclusive global rights to develop and commercialize multiple advanced compounds through a license agreement with AbbVie. This strategic acquisition includes Phase 2 compounds ABBV-2222 and ABBV-3067, and Phase 1 compound ABBV-2851, bolstering Sionna’s pipeline and its position in the CF […]
Read more

Gilead’s lenacapavir holds greater potential in reducing HIV incidence than currently marketed drugs, says GlobalData

At the 25th International AIDS Conference (AIDS 2024) that took place from July 22-26 in Munich, Germany, Gilead presented full efficacy and safety results for its Phase III PURPOSE 1 HIV prevention trial for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor. Lenacapavir demonstrated zero infections and 100% efficacy, as well as superior prevention of HIV […]
Read more

Phase III post-marketing commitment study data paves way for usage of Paratek’s Nuzyra in other indications, says GlobalData

Paratek Pharmaceuticals has announced positive topline efficacy and safety data from a global, Phase III post-marketing commitment study of its novel antibiotic, a next-generation tetracycline, Nuzyra (omadacycline). In a study of 670 adults with moderate to severe community-acquired bacterial pneumonia (CABP), Nuzyra was found to be generally safe and well-tolerated. The drug met both primary […]
Read more

NewAmsterdam’s obicetrapib holds potential to become first CETP inhibitor to advance to clinical practice, says GlobalData

NewAmsterdam Pharma has completed the enrollment of 407 patients in the pivotal Phase III TANDEM clinical trial evaluating obicetrapib in combination with ezetimibe in patients with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD). Obicetrapib has demonstrated strong tolerability in more than 800 patients with elevated lipid levels in NewAmsterdam’s clinical trials to date. […]
Read more
1 … 15 16 17 18 19 … 108